Insights Into Acute Myeloid Leukemia (AML)

Perspectives of community physicians on the treatment of acute myeloid leukemia (AML) , recently introduced and upcoming agents

July 20, 2021
Purchase Report

Faculty Chair

Elias Jabbour, MD

The University of Texas MD Anderson Cancer Center, Houston, TX, USA

More information

  • Virtual series

Example Agenda

Download the meeting agenda

View Agenda

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • A virtual, moderated roundtable discussion focusing on the treatment of acute myeloid leukemia
  • Disease state and data presentations were developed in conjunction with a national or regional oncology expert
  • Insights on the following AML therapies were obtained: venetoclax, gilteritinib, CC-486, azacitidine, cytarabine and daunorubicin (ie, 7+3), CPX-351, ivosidenib, gemtuzumab ozogamicin, midostaurin, and sorafenib

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • Data collection was accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors comprised 10–15 medical oncologists

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.